Results 151 to 160 of about 484,803 (308)

Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma

Alimentary Pharmacology &Therapeutics, EarlyView.
Patients who received immune checkpoint inhibitors before liver transplant for the treatment of hepatocellular carcinoma had rejection and survival outcomes comparable to those without ICI exposure. Most rejection episodes were effectively managed with medical therapy.
L. Aceituno, C. Magyar, P. Tabrizian, R. Marino, K. Watt, D. Chascsa, G. Schnickel, V. Banz, F. Alconchel, Celia Martagon, C. Moctezuma, T. Baker, C. Nwaduru, F. J. Krendl, R. Oberhuber, L. Ruiz‐Ortega, C. Demers, R. Bucur, G. O'Kane, A. Vogel, B. Mínguez, G. Sapisochin   +21 more
wiley   +1 more source

Single‐Cell and Multiomic Analysis Reveals Neutrophil Heterogeneity and Prognostic Value in Cervical Lesions

Cancer Science, EarlyView.
This study is the first to identify a novel neutrophil subpopulation, N4, that is closely associated with the progression of cervical cancer. Characterized by high PLAU expression and specific interactions with tumor cells, N4 neutrophils were shown to promote tumor growth and immune modulation.
Ze Wang, Liang Zhuang, Shiyi Liu, Canhui Cao, Shimin Chen, Nan Yu, Xiaoyuan Huang, Tao Zhang   +7 more
wiley   +1 more source

Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

International Journal of Dermatology, EarlyView.
Meta‐analysis of randomized controlled trials shows that switching from calcineurin inhibitors (CNI) to sirolimus in kidney transplant recipients (KTRs) with prior cutaneous squamous cell carcinoma (cSCC) reduces secondary cSCC incidence but increases adverse‐event–related treatment discontinuation.
Yannick Foerster, Julia Palaras, Kristine Mayer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Interferon Regulatory Factor 2 (IRF2) Suppression Enhances Murine Cardiac Allograft Survival Through Immune Evasion

Immunology, EarlyView.
Our data show that suppressing IRF2, genetically or by siRNA, modulates PD‐L1 and MHC‐I levels. This induced immune‐evasive state critically underlies the significantly prolonged survival of cardiac allografts, revealing a novel therapeutic avenue.
Li Tian, Man Zhang, Yuliang Guo, Sheng Chang, Zhonghua Klaus Chen, Hongmin Zhou   +5 more
wiley   +1 more source

Porphyromonas gingivalis GroEL exacerbates orthotopic allograft transplantation vasculopathy via impairment of endothelial cell function

Molecular Oral Microbiology, EarlyView.
Abstract Orthotopic allograft transplantation (OAT) is a significant approach to addressing organ failure. However, persistent immune responses to the allograft affect chronic rejection, which induces OAT vasculopathy (OATV) and organ failure. Porphyromonas gingivalis can infiltrate remote organs via the bloodstream, thereby intensifying the severity ...
Chien‐Sung Tsai, Chun‐Yao Huang, Yi‐Ting Tsai, Chun‐Ming Shih, Ze‐Hao Lai, Chen‐Wei Liu, Yi‐Wen Lin, Feng‐Yen Lin   +7 more
wiley   +1 more source

The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation

Transplant Infectious Disease, EarlyView.
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam, Abdinoor Abdi, Wyatt Tarter, Ben Langworthy, Adam Bregman, Karam M. Obeid   +5 more
wiley   +1 more source

Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney‐Transplant and Hematopoietic Cell Transplant Recipients

Transplant Infectious Disease, EarlyView.
Third‐party, BK virus‐specific cytotoxic T lymphocytes (CTLs) were safe and effective in reducing viremia in kidney and stem cell transplant recipients with BK virus nephropathy. However, they did not improve kidney function. Earlier administration may be more beneficial before nephropathy and irreversible damage occur.
Amanda Olson, Ye Ethan Li, Rafet Basar, Pinaki Banerjee, Indresh Kaur, Glorette Abueg, Melihate Sylejmani, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Valda Page, Richard E. Champlin, Dimitrios P. Kontoyiannis, Roy F. Chemaly, Elizabeth J. Shpall, Linda Moore, Osama A. Gaber, Katayoun Rezvani, Ala Abudayyeh   +18 more
wiley   +1 more source

The effect of perioperative erythropoietin‐stimulating agents and intravenous iron on patient outcomes following solid organ transplantation: A systematic review

Transfusion Medicine, EarlyView.
Abstract Solid organ transplant is associated with high rates of anaemia and transfusion, but there is little comparative data on interventions such as erythropoietin‐stimulating agents (ESAs) and intravenous (IV) iron. We conducted a systematic review examining the association of ESAs and IV iron with outcomes in adults undergoing solid organ ...
Frank Lee, Quentin Eichbaum, Christine Cserti‐Gazdewich, Darren Mullane, Frederick W. Lombard, Jeremy W. Jacobs, Katerina Pavenski, Marina Englesakis, Alexander Dotto, Terry Cho, Andrés Leonard‐Reixa, Jacqueline Trudeau, Andrew W. Shih, Justyna Bartoszko   +13 more
wiley   +1 more source

Exploring the immunomodulatory impacts of blood manufacturing consolidation

Transfusion, EarlyView.
Abstract Introduction The immunomodulatory consequences of blood transfusion, known as transfusion‐related immune modulation (TRIM), are often not captured by hemovigilance systems. Changes to blood product manufacturing processes may impact patient outcomes.
Amanda Kauffman, Michelle P. Zeller, Yang Liu, Jason P. Acker, Donald M. Arnold, Nancy Heddle, Chris Hillis, Na Li, Bram Rochwerg, Kayla Lucier, Summer Syed, Shuoyan Ning   +11 more
wiley   +1 more source